0.59% 0.0864

다케다약품공업 ADR (TAK)

개요 뉴스 가격 이력 옵션 체인 토론 예측 배당 이력

Relative Volume:

다케다약품공업 ADR Stock (TAK) Company Profile

Takeda Pharmaceutical Co Adr

Healthcare (1154)

@takedapharma

최신 SEC 제출 서류

TAK's Discussions on Twitter

TAK을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
TAK Takeda Pharmaceutical Co Adr	15.23	47.88B	29.96B	957.25M	4.77B	0.304
ZTS Zoetis Inc	152.06	67.75B	9.39B	2.62B	2.22B	5.81
HLN Haleon Plc Adr	9.875	43.70B	14.26B	1.98B	2.47B	0.4347
TEVA Teva Pharmaceutical Industries Ltd Adr	18.64	21.51B	16.70B	-157.13M	1.19B	-0.155
UTHR United Therapeutics Corp	384.17	18.31B	2.99B	1.21B	1.13B	25.06

다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-04-02	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2023-03-16	업그레이드	BofA Securities	Neutral → Buy
2022-07-19	업그레이드	Cowen	Market Perform → Outperform
2021-10-07	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-04-19	다운그레이드	JP Morgan	Overweight → Neutral
2019-11-01	개시	Cowen	Market Perform
2019-08-15	다운그레이드	Daiwa Securities	Outperform → Neutral

다케다약품공업 ADR 주식(TAK)의 최신 뉴스

다케다약품공업 ADR (TAK) 재무 분석

다케다약품공업 ADR (TAK)

다케다약품공업 ADR Stock (TAK) Company Profile

TAK을(를) 다른 주식과 비교

다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades

다케다약품공업 ADR 주식(TAK)의 최신 뉴스

Hodgkin’s Lymphoma Market Set to Reach New Heights by 2034 with Innovative Therapies and Clinical Successes | DelveInsight - GlobeNewswire Inc.

Japan's Takeda weighs India for global trials to speed up drug launches - MSN

Takeda Pharmaceutical ADR Earns RS Rating Upgrade - MSN

IBD Rating Upgrades: Warrior Met Coal Shows Improved Technical Strength - inkl

IBD Rating Upgrades: Takeda Pharmaceutical ADR Shows Improved Technical Strength - MSN

IBD Rating Upgrades: Ameren Shows Improved Technical Strength - inkl

TAK’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com

Blair William & Co. IL Cuts Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK) - Defense World

Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Stock Market Dynamics - investchronicle.com

Asian ADRs Fall As Winners And Losers Stand Out - Finimize

The 30-day ADR trend, in yen terms, shows high values for Keyence, Kyocera Corporation Sponsored ADR, and Murata Manufacturing. - 富途牛牛

Takeda Pharma ADR earnings beat by $150.82, revenue fell short of estimates - Investing.com UK

On the 21st, ADR movements in yen terms showed high values for NISSAN MOTOR CO LTD, NINTENDO CO LTD, and Sumitomo Trust. - 富途牛牛

Why This Biotech's Dive Benefits Its Top Three Rivals - Investor's Business Daily

Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector (TAK) - Seeking Alpha

Behind Takeda Pharmaceutical Co ADR’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com

Takeda stock rises after positive Phase 3 results for narcolepsy drug - Investing.com

Takeda stock rises after positive Phase 3 results for narcolepsy drug By Investing.com - Investing.com South Africa

Haleon PLC Sponsored ADR (NYSE:HLN) Shares Purchased by Allspring Global Investments Holdings LLC - Defense World

Nomura Holdings Inc ADR (NYSE:NMR) Shares Acquired by GAMMA Investing LLC - Defense World

Hengan International Group (OTCMKTS:HEGIY) Stock Price Up 3.7% – Time to Buy? - Defense World

Expedia Group Earns RS Rating Upgrade - inkl

GAMMAGARD LIQUID ERC, GAMMAGARD LIQUID and GAMMAGARD S/D U.S. Important Safety Information - Placera.se

Stocks With Rising Relative Price Strength: IREN - inkl

Stocks With Rising Relative Strength: Dr. Reddy's Labs ADR - inkl

Nano Dimension Ltd ADR’s Shares Reel: -28.07% Quarterly Revenue Decline Amid 329.06M Market Cap - investchronicle.com

MNST’s Stock Market Adventure: 19.08% YTD Growth Amidst Volatility - investchronicle.com

On the 10th, the ADR trends show that Takeda Pharmaceutical, Nidec Corporation Sponsored ADR, Advantest, and others are performing well in terms of yen conversion. - 富途牛牛

SEC Form N-CSRS filed by abrdn World Healthcare Fund Shares of Beneficial Interest - Quantisnow

EU approves Takeda’s new Hodgkin lymphoma treatment - Investing.com

IgA nephropathy Pipeline Drugs Analysis 2025: Clinical Trials, - openPR.com

CTVA’s Stock Market Adventure: 22.38% YTD Growth Amidst Volatility - investchronicle.com

Takeda files executive compensation report with SEC - Investing.com

Cameco Earns Relative Strength Rating Upgrade; Hits Key Threshold - inkl

TD Cowen maintains Buy on Takeda, reiterates $16 target - Investing.com

Stocks With Rising Relative Strength: Novartis ADR - inkl

Fidelity Natl Info Svcs Shows Rising Relative Strength; Still Shy Of Key Benchmark - inkl

Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus - Wiley Online Library

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Stocks Soar as Investors Cheer US-China Tariff Rollback - Morningstar

Financial Metrics Unveiled: Topgolf Callaway Brands Corp (MODG)’s Key Ratios in the Spotlight - DWinneX

Ratios Reveal: Breaking Down Takeda Pharmaceutical Co ADR (TAK)’s Financial Health - DWinneX

Balance Sheet Insights: Nuveen Churchill Direct Lending Corp (NCDL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX

Takeda continues stock plan for management in 2025 - Investing.com

Novavax revises Takeda deal for Japan vaccine sales - Investing.com

TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance

Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - knoxdaily.com

다케다약품공업 ADR (TAK) 재무 분석

매출

순이익

현금흐름

주당 순 이익

TAK과 유사한 종목